A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer
← catalyst calendarNCT07169851 · readout ≤ 133 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
204estimated
Sites
67
Countries
Australia, China, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-28 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Nausea
- Vomiting
- Drug-Related Side Effects and Adverse Reactions
- Neoplasms
Interventions
- Drug: LY3537021
- Drug: Placebo
- Drug: Standard of Care Antiemetic Therapies
- Drug: Background Chemotherapy
Primary outcome
what the primary-completion date above is the date OFProportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV
measured 24 to 120 hours after first chemotherapy infusion
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed